Literature DB >> 30188868

Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.

Sean T H Liu1,2, Mohammad Amin Behzadi1, Weina Sun1, Alec W Freyn1, Wen-Chun Liu1, Felix Broecker1, Randy A Albrecht1,3, Nicole M Bouvier1,2, Viviana Simon1,3, Raffael Nachbagauer1, Florian Krammer1, Peter Palese1.   

Abstract

Hemagglutination inhibition (HI) titers are a major correlate of protection for influenza-related illness. The influenza virus hemagglutinin possesses antigenic sites that are the targets of HI active antibodies. Here, a panel of mutant viruses each lacking a classically defined antigenic site was created to compare the species-specific immunodominance of the antigenic sites in a clinically relevant hemagglutinin. HI active antibodies of antisera from influenza virus-infected mice targeted sites Sb and Ca2. HI active antibodies of guinea pigs were not directed against any specific antigenic site, although trends were observed toward Sb, Ca2, and Sa. HI titers of antisera from infected ferrets were significantly affected by site Sa. HI active antibodies of adult humans followed yet another immunodominance pattern, in which sites Sb and Sa were immunodominant. When comparing the HI profiles among different species by antigenic cartography, animals and humans grouped separately. This study provides characterizations of the antibody-mediated immune responses against the head domain of a recent H1 hemagglutinin in animals and humans.

Entities:  

Keywords:  Adaptive immunity; Immunology; Influenza; Virology

Mesh:

Substances:

Year:  2018        PMID: 30188868      PMCID: PMC6205383          DOI: 10.1172/JCI122895

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Structural basis of immune recognition of influenza virus hemagglutinin.

Authors:  I A Wilson; N J Cox
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

2.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

3.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

4.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 5.  Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift.

Authors:  Meghan O Altman; Davide Angeletti; Jonathan W Yewdell
Journal:  Viral Immunol       Date:  2018-01-22       Impact factor: 2.257

6.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection.

Authors:  Suzanne E Ohmit; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Arnold S Monto
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

8.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

9.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

10.  Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Authors:  Brendan Flannery; Jessie R Chung; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Angie Foust; Wendy Sessions; LaShondra Berman; John R Barnes; Sarah Spencer; Alicia M Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-02-16       Impact factor: 17.586

View more
  23 in total

1.  The post-2009 influenza pandemic era: time to revisit antibody immunodominance.

Authors:  Kristien Van Reeth
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

2.  Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Authors:  Florian Krammer; Peter Palese
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 3.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

4.  Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology.

Authors:  Waleed Javaid; Jordan Ehni; Ana S Gonzalez-Reiche; Juan Manuel Carreño; Elena Hirsch; Jessica Tan; Zenab Khan; Divya Kriti; Thanh Ly; Bethany Kranitzky; Barbara Barnett; Freddy Cera; Lenny Prespa; Marie Moss; Randy A Albrecht; Ala Mustafa; Ilka Herbison; Matthew M Hernandez; Theodore R Pak; Hala A Alshammary; Robert Sebra; Melissa L Smith; Florian Krammer; Melissa R Gitman; Emilia Mia Sordillo; Viviana Simon; Harm van Bakel
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

5.  Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans.

Authors:  Weina Sun; Davina S Kang; Allen Zheng; Sean T H Liu; Felix Broecker; Viviana Simon; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 6.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

Review 7.  Influenza Virus and SARS-CoV-2 Vaccines.

Authors:  Adam M Sandor; Michael S Sturdivant; Jenny P Y Ting
Journal:  J Immunol       Date:  2021-05-21       Impact factor: 5.426

Review 8.  Host immune response-inspired development of the influenza vaccine.

Authors:  Angela Choi; Adolfo García-Sastre; Michael Schotsaert
Journal:  Ann Allergy Asthma Immunol       Date:  2020-04-20       Impact factor: 6.347

Review 9.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

10.  Antiviral Activities of Hibiscus sabdariffa L. Tea Extract Against Human Influenza A Virus Rely Largely on Acidic pH but Partially on a Low-pH-Independent Mechanism.

Authors:  Yohei Takeda; Yuko Okuyama; Hiroto Nakano; Yasunori Yaoita; Koich Machida; Haruko Ogawa; Kunitoshi Imai
Journal:  Food Environ Virol       Date:  2019-10-16       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.